S 10260 NY
Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state
A state bill is a proposed law in a state legislature — separate from the U.S. Congress. Learn more →
Summary
This bill amends New York law to add five rare genetic diseases to the state's newborn screening panel: CLN2 (Late-infantile neuronal ceroid lipofuscinosis type 2), MPS IVA (Mucopolysaccharidosis type IVA), MPS VI (Mucopolysaccharidosis type VI), MPS VII (Mucopolysaccharidosis type VII), and Fabry disease. The bill requires the Department of Health to make tests for these diseases available within twelve months of the effective date. These tests will be added to the routine newborn screening that all infants in New York receive. The bill takes effect immediately.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Official abstract
Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.
Sponsor (1)
- Lea Webb Democratic · primary
2 coauthors / cosponsors
- Kevin S. Parker Democratic · cosponsor
- Christopher Ryan Democratic · cosponsor
Action history (1)
- May 8, 2026 REFERRED TO HEALTH · upper
Text versions (2)
Full text
Full text imported from assembly.state.ny.us
Skip to main content
New York State Assembly Speaker Carl E. Heastie
--> --> -->
Assembly Members
Legislative Info
Public Hearings
Speaker's Press
Assembly Reports
Committees & More
Bill Search Home Laws Legislative Calendar Public Hearing Schedule Assembly Calendars Assembly Committee Agenda Javascript must be enabled to properly view this page.
Bill No.: Summary Actions Committee Votes Floor Votes Memo Text LFIN Chamber Video/Transcript S10260 Summary: BILL NO S10260   SAME AS SAME AS A10521-A
  SPONSOR WEBB   COSPNSR PARKER, RYAN C   MLTSPNSR   Amd §2500-a, Pub Health L   Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.
Go to top S10260 Text:
STATE OF NEW YORK ________________________________________________________________________
10260
IN SENATE
May 8, 2026 ___________
Introduced by Sen. WEBB -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law, in relation to newborn screening for CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases
The People of the State of New York, represented in Senate and Assem- bly, do enact as follows:
1 Section 1. Subdivision 1 of section 2500-a of the public health law is 2 amended by adding five new paragraphs (l), (m), (n), (o) and (p) to read 3 as follows: 4 (l) Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). 5 (m) Mucopolysaccharidosis type IVA (MPS IVA). 6 (n) Mucopolysaccharidosis type VI (MPS VI). 7 (o) Mucopolysaccharidosis type VII (MPS VII). 8 (p) Fabry. 9 § 2. Section 2500-a of the public health law is amended by adding a 10 new subdivision 4 to read as follows: 11 4. The commissioner shall ensure tests are made available for all 12 diseases and conditions designated pursuant to paragraphs (l), (m), (n), 13 (o) and (p) of subdivision one of this section within twelve months of 14 the effective date of such paragraphs. 15 § 3. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD15047-03-6
Go to top
Sitemap
Request Information
Directions and Maps
Comments
Data from OpenStates. View on OpenStates →
Comments